Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2025-02-25 00:00:00 ET · period of report 2025-02-21 · accession 0000905148-25-000764 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-25 | 2025-02-21 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $5.54 | -19.9K | 2.29M | -0.9% | -$110.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-21 | F | D | 19,904 | $5.54 | 2,285,781 | D | — | — | (F2) These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. |